Follow The Filings

LXRX Lexicon Pharmaceuticals

Lexicon Pharmaceuticals earnings company data as of 4:47 AM ET 10/24

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 5 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by LXRX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All LXRX insider trades
  • $2.7M bought by 2 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Raymond Debbane Director
    Buy
    $2,980 2,000 shares at $1.49 +0.1% to stake
    Traded Feb 25 Filed Feb 27
    ↗
  2. Raymond Debbane Director
    Buy
    $147K 100,000 shares at $1.47 +5.5% to stake
    Traded Feb 23 Filed Feb 25
    ↗
  3. Raymond Debbane Director
    Buy
    $220K 150,000 shares at $1.47 +9.1% to stake
    Traded Feb 19–20 Filed Feb 23
    ↗
  4. Raymond Debbane Director
    Buy
    $353K 268,497 shares at $1.31 +19% to stake
    Traded Feb 13–18 Filed Feb 18
    ↗
  5. Invus Global Management, LLC Director, +8 joint filers
    Buy
    $2M 1,538,462 shares at $1.30 New stake
    Traded Feb 2 Filed Feb 4
    ↗

Also filed in the last 12 months, not counted as buying or selling: 25 option exercises, 8 share withholdings for taxes, and 4 stock grants.

SEC filings

Recent issuer filings from EDGAR, 12 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 1.01,2.03,3.02,7.01,9.01 Filing Doc
8-K 1.01,3.02,5.03,5.07,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A DEF 14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc

Source: SEC EDGAR submissions, updated 6 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.